1173 related articles for article (PubMed ID: 9263350)
21. [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].
Brière J
Bull Acad Natl Med; 2007 Mar; 191(3):535-48. PubMed ID: 18072652
[TBL] [Abstract][Full Text] [Related]
22. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
[TBL] [Abstract][Full Text] [Related]
23. A standardized endogenous megakaryocytic erythroid colony assay for the diagnosis of essential thrombocythemia.
Dobo I; Boiret N; Lippert E; Girodon F; Mossuz P; Donnard M; Campos L; Pineau D; Bascans E; Praloran V; Hermouet S
Haematologica; 2004 Oct; 89(10):1207-12. PubMed ID: 15477205
[TBL] [Abstract][Full Text] [Related]
24. The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera.
Abdulkarim K; Ridell B; Johansson P; Kutti J; Safai-Kutti S; Andréasson B
Eur J Haematol; 2011 Feb; 86(2):148-55. PubMed ID: 21059102
[TBL] [Abstract][Full Text] [Related]
25. Polycythemia vera: scientific advances and current practice.
Tefferi A; Spivak JL
Semin Hematol; 2005 Oct; 42(4):206-20. PubMed ID: 16210034
[TBL] [Abstract][Full Text] [Related]
26. Value of bone marrow biopsy in the diagnosis of essential thrombocythemia.
Florena AM; Tripodo C; Iannitto E; Porcasi R; Ingrao S; Franco V
Haematologica; 2004 Aug; 89(8):911-9. PubMed ID: 15339673
[TBL] [Abstract][Full Text] [Related]
27. Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients.
Thiele J; Kvasnicka HM
Ann Hematol; 2003 Mar; 82(3):148-52. PubMed ID: 12634946
[TBL] [Abstract][Full Text] [Related]
28. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
29. [Prognostic value of bone marrow biopsy in chronic myeloproliferative disorders].
Bettini R; Marzetta K; Miglioranza A; Redaelli S; Maino C; Maffiolini A; Gorini M
Recenti Prog Med; 2003; 94(7-8):314-20. PubMed ID: 12868237
[TBL] [Abstract][Full Text] [Related]
30. Prognostic and diagnostic value of endogenous erythroid colony formation in essential thrombocythemia.
Ciaudo M; Hadjez JM; Teyssandier I; Coly E; Zittoun R; Marie JP
Hematol Cell Ther; 1998 Aug; 40(4):171-4. PubMed ID: 9766922
[TBL] [Abstract][Full Text] [Related]
31. The role of beta-catenin in chronic myeloproliferative disorders.
Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC
Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
[TBL] [Abstract][Full Text] [Related]
32. Expression of Bcl-x in erythroid precursors from patients with polycythemia vera.
Silva M; Richard C; Benito A; Sanz C; Olalla I; Fernández-Luna JL
N Engl J Med; 1998 Feb; 338(9):564-71. PubMed ID: 9475763
[TBL] [Abstract][Full Text] [Related]
33. Prediction of clinical course in patients with idiopathic erythrocytosis by endogenous erythroid colony assay but not by serum erythropoietin levels.
Shih LY; Lee CT; Ou YC
Exp Hematol; 1997 Apr; 25(4):288-92. PubMed ID: 9131002
[TBL] [Abstract][Full Text] [Related]
34. In vitro erythropoiesis in polycythemia vera and other myeloproliferative disorders.
Weinberg RS
Semin Hematol; 1997 Jan; 34(1):64-9. PubMed ID: 9025164
[TBL] [Abstract][Full Text] [Related]
35. [Histological diagnosis of Ph-negative myeloproliferative neoplasia. An overview].
Campr V
Cesk Patol; 2011 Jul; 47(3):84-93. PubMed ID: 21887923
[TBL] [Abstract][Full Text] [Related]
36. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
37. Endogenous erythroid and megakaryocytic colony formation in serum-free, cytokine-free collagen gels.
Dobo I; Pineau D; Zandecki M; Hunault M; Hermouet S
J Hematother Stem Cell Res; 1999 Dec; 8(6):601-7. PubMed ID: 10645767
[TBL] [Abstract][Full Text] [Related]
38. Erythropoietin-independent erythroid colony formation by bone marrow progenitors exposed to interleukin-11 and interleukin-8.
Corre-Buscail I; Pineau D; Boissinot M; Hermouet S
Exp Hematol; 2005 Nov; 33(11):1299-308. PubMed ID: 16263414
[TBL] [Abstract][Full Text] [Related]
39. Megakaryopoiesis in chronic myeloproliferative diseases. A morphometric evaluation with special emphasis on primary thrombocythemia.
Thiele J; Funke S; Holgado S; Choritz H; Georgii A
Anal Quant Cytol; 1984 Sep; 6(3):155-67. PubMed ID: 6594964
[TBL] [Abstract][Full Text] [Related]
40. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
